Please login to the form below

Not currently logged in
Email:
Password:

Approvals of generic Eloxatin suspended

A US appeals court has temporarily suspended approvals of generic versions of sanofi-aventis' Eloxatin, delaying competition to its fifth-biggest medicine

A US appeals court has temporarily suspended approvals of generic versions of sanofi-aventis' Eloxatin (oxaliplatin), delaying competition to its fifth-biggest medicine.

France's largest drugmaker has contested the US Food and Drug Administration's (FDA) decision to approve copies of the treatment. The ruling forces rivals, including Hospira and Teva who recently obtained FDA approval, to halt shipments of the drug.

Teva spokesperson Denise Bradley confirmed that the company is "not shipping further product until the legal issue is resolved… We are hopeful to have a decision in the near future."

Hospira stated in a US Securities and Exchange Commission filing that the suspension remains in effect "until such time as the court has an opportunity to consider arguments on this matter."

Eloxatin generated €1.35bn ($1.9bn) in sales for sanofi-aventis last year. The company is under pressure as several of its best-selling drugs, including the blood-thinner Plavix, face generic competition.

18th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics